Glacier Bancorp, Inc. Announces Third Quarter Earnings

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Glacier Bancorp, Inc. Announces Third Quarter Earnings Release and Conference Call

KALISPELL, Mont., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Glacier Bancorp, Inc. (Nasdaq: GBCI ) will report third quarter financial results after the market closes on October 24, 2013. A conference call for investors is scheduled for 11:00 a.m. Eastern Time on Friday, October 25, 2013.

The conference call will be accessible by telephone and through the Internet. Interested individuals are invited to listen to the call by telephone at 877-561-2748 and the conference ID is 73729037.

To participate on the webcast, log on to: http://www.media-server.com/m/p/frseyxge . If you are unable to participate during the live webcast, the call will be archived on our Web site, www.glacierbancorp.com until October 31, 2013.

This presentation will include forward looking statements, which describe management's expectations regarding future events and developments such as future operating results, growth in loans and deposits, continued success of the Company's style of banking and the strength of the local economies in which it operates. Future events are difficult to predict, and the expectations described above are necessarily subject to risk and uncertainty that may cause actual results to differ materially and adversely. In addition to discussions about risks and uncertainties set forth from time to time in the Company's public filings, factors that may cause actual results to differ materially from those contemplated by such forward looking statements include, among others, the following possibilities: (1) local, national and international economic conditions are less favorable than expected or have a more direct and pronounced effect on the Company than expected and adversely affect the Company's ability to continue its internal growth at historical rates and maintain the quality of its earning assets; (2) changes in interest rates reduce interest margins more than expected and negatively affect funding sources; (3) projected business increases following strategic expansion or opening or acquiring new banks and/or branches are lower than expected; (4) costs or difficulties related to the integration of acquisitions are greater than expected; (5) competitive pressure among financial institutions increases significantly; (6) legislation or regulatory requirements or changes adversely affect the businesses in which the Company is engaged.

Glacier Bancorp, Inc. is the parent company for Glacier Bank, Kalispell and its bank divisions: First Security Bank of Missoula; Valley Bank of Helena; Big Sky Western Bank, Bozeman; Western Security Bank, Billings; and First Bank of Montana, Lewistown, all located in Montana; as well as Mountain West Bank, Coeur d'Alene, operating in Idaho, Utah and Washington; 1 st Bank, Evanston, operating in Wyoming and Utah; Citizens Community Bank, Pocatello, operating in Idaho; Bank of the San Juans, Durango, operating in Colorado; First Bank of Wyoming, Powell, and First State Bank, Wheatland, operating in Wyoming; and North Cascades Bank, Chelan, operating in Washington.

Michael J. Blodnick (406) 751-4701 Ron J. Copher (406) 751-7706

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Embla Medical hf Reports Strong Q2 2025 Financial Performance

Updated Category News Views 203

Embla Medical hf's Interim Report for Q2 2025 Announcement No. 33/2025 Interim Report Q2 2025 Embla Medical hf has recently published its interim report for the second quarter of 2025, revealing encouraging financial results. The organization remains committed to enhancing mobility solutions through innovative offerings in prosthetics and orthotics. Strong Sales Growth...

Continue Reading
Fly-E Group Faces Important Class Action Deadline for Investors

Updated Category News Views 185

Fly-E Group Update: Important Class Action Deadline Attention investors of Fly-E Group, Inc. If you purchased securities between July 15 and August 14, 2025, this is vital news for you. As we approach a crucial lead plaintiff deadline on November 10, 2025, the time to act is now. Understanding the Class Action The upcoming class action lawsuit revolves around Fly-E's...

Continue Reading
Royal Unibrew Posts Impressive Earnings Growth in Q3 2024

Updated Category News Views 173

Royal Unibrew's Remarkable Performance in Q3 2024 Royal Unibrew has demonstrated exceptional growth during the third quarter of 2024. The key highlights from this trading statement reveal a robust progression in organic volume and net revenue, paving the way for a bright future for the company. Strong Growth Metrics Organic Volume and Revenue Increases During Q3 2024,...

Continue Reading
Examining Medtronic PLC's Short Selling Trends and Insights

Updated Category News Views 184

Understanding Medtronic PLC's Short Interest Medtronic PLC (NYSE: MDT) has recently experienced a significant rise in its short interest as a percentage of float, currently at 17.56%. This increase signals a growing concern among investors, as the total number of shares sold short has reached 19.72 million, accounting for 1.54% of all available shares for trading. With...

Continue Reading
Palatin Technologies Announces Breakthrough in Obesity Management

Updated Category News Views 138

Positive Developments in Appetite Suppression Research Palatin Technologies, Inc. (NYSE American: PTN), a leading biopharmaceutical firm known for pioneering medications based on the melanocortin receptor system, has recently reported encouraging results concerning appetite suppression from its Phase 2 obesity study involving bremelanotide and tirzepatide. This...

Continue Reading